Released: 01/09/2023 Expires: 12/31/2023 (subject to change)
CE for this activity will not be available after this date.
Overview Before the Covid-19 pandemic began, approximately 6.5% of the population in the US had symptoms of MDD. Since the onset of the Covid-19 pandemic, the proportion of the US population reporting MDD symptoms has increased to 21-30% during any one time period measured. NPs are important members of the healthcare team responsible for screening, identifying and treating MDD. This monograph activity contains text, infographics, tables and case studies to prepare you to screen, identify, treat and monitor patients with MDD. Objectives
Compare new and emerging pharmacologic treatment options for patients with MDD, including initial treatments, and those for patients with an inadequate initial response or treatment-refractory MDD.
Evaluate the importance of prompt diagnosis of MDD to prevent negative effects on patient quality of life, morbidity, and mortality.
Measure response to antidepressant treatment to assess if a patient will benefit from alternative or adjunctive interventions.
Apply evidence-based and guideline-recommended strategies for the individualization of antidepressant treatment options.
Speakers Brayden N. Kameg, DNP, PMHNP-BC, CARN-AP, CNE Lisa M. Anderson, DNP, APRN, PMHNP-BC
Disclosure This program was planned in accordance with AANP CE Standards and Policies.
Brayden N. Kameg and Lisa M. Anderson have no relevant financial relationships to disclose. All Planners involved in this activity have no relevant financial relationships to disclose.
This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Disclaimer Individuals who have contributed to the CE Center were carefully selected for their knowledge and experience in the subject area under review. This presentation is informational only and may contain opinions of the authors from their personal experience that do not necessarily express the opinions of the American Association of Nurse Practitioners (AANP). The activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Clinical practice is a constantly changing process and new information becomes available every day. Neither AANP nor the contributing individuals can warrant that the material will continue to be accurate, nor do they warrant that the material is completely free of errors upon publication. Attendees and participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program. CE Credit Instructions
Read this activity description, including objectives and disclosures.
Complete the Pretest associated to the activity.
Complete the educational content:
Monograph Presentations: Click the Play button to get access to the downloadable PDF monograph of the activity. Learners will be required to read all presented material in the PDF.
Click on the Additional Resources button to review all additional materials provided (handouts, post-test reviews, any other downloadable resources).
After completing all content, click on the blue Next Steps button:
Complete the affidavit confirming that you've reviewed all required content for the activity.
Complete the post-test.
Submit the evaluation to receive full AANP CE/Rx credit.
Additional Information For questions or more information concerning this online CE opportunity contact the AANP CE Center Support team at CECenter@aanp.org.
1 Contact Hour(s) of CE, 0.5 of which may be applied towards Pharmacology